abbott labs posts

Feed

The Timely Ten: Blue Chip Dividends

Procter and Gamble (PG) logo"Our goal is helping investors grow their capital and income base from which to derive cash for their current and future needs," notes dividend expert Kelley Wright.

The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation. Our Timely Ten list represents our current top ideas.

Continue reading The Timely Ten: Blue Chip Dividends

A Growth and Income Trio for All Investors

growth and income"It seems plausible to expect the index to return about 13% in the coming year; not exactly a runaway bull, but a bright enough prospect to keep us in the game," says blue chip expert Richard Band.

The editor of Profitable Investing explains, "Here are three growth-and-income names that I deem suitable for virtually all investors of any age: Abbott Laboratories (ABT), Sysco (SYY) and Time Warner (TWX).

"Whether you're three years or 33 years from retirement, now is a good time to stock up on this trio of growth and income recommendations.

Continue reading A Growth and Income Trio for All Investors

Analyst Calls: ABT, ALU, CSCO, EL, F, KKR, QCOM, RIMM, SAP, STP, TIVO ...

Analyst Upgrades

  • Qualcomm (QCOM) was upgraded to outperform from neutral at Credit Suisse.
  • JPMorgan upgraded Allegheny Tech (ATI) to overweight from neutral.
  • NetApp (NTAP) was upgraded to buy from hold at Canaccord.
  • Estee Lauder (EL) was upgraded to perform from underperform at Oppenheimer.
  • Citigroup upgraded Suntech (STP) to hold from sell.

Continue reading Analyst Calls: ABT, ALU, CSCO, EL, F, KKR, QCOM, RIMM, SAP, STP, TIVO ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Upgrades

  • Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
  • JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
  • Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
  • Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
  • Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
  • Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Abbott Labs to Acquire Facet Biotech

After the closing bell Tuesday, Abbott Laboratories (ABT) announced that it will acquire Facet Biotech (FACT) for $27 per share. The transaction carries a total price tag of $722 million. Including $272 million of FACT's cash and securities, the net cost turns out to be roughly $450 million.

Back in December, FACT turned down Biogen Idec's (BIIB) unsolicited takeover offer of $17.50 per share. The deal is expected to close in the second quarter, as both boards of directors have approved the deal.

Continue reading Abbott Labs to Acquire Facet Biotech

Quality Yields: IQ Trend's Timely Ten

"Our primary purpose is to assist investors in growing their capital and income base from which to derive cash for their current and future needs," says Kelley Wright.

The editor of IQ Trends -- and author of the just-released book Dividends Still Don't Lie -- explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.

Continue reading Quality Yields: IQ Trend's Timely Ten

Chasing Value: Ten stocks for 2010 -- Part 9 + Apple

Is it time to take a bite out of Apple, Inc (AAPL) or leave it on the vine? After reviewing the current list by examining the stock yields and price-to-cash flow (P/CF) we will take a look at Apple for 2010.

Yesterday I dropped two stocks, but the list is still too long. In the coming weeks there will be more cuts and if I find anything of more value perhaps there will be something new.

Continue reading Chasing Value: Ten stocks for 2010 -- Part 9 + Apple

Turnaround expert targets laggard pharmaceuticals

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Goldman Sachs upgraded the banking sector last week, and this coming week we'll get a chance to see whether Goldman and other big banks reporting third quarter results will live up to the expectations of analysts surveyed by Thomson Reuters.

New York-based Goldman Sachs Group Inc. (NYSE: GS) looks set to be this week's earnings game winner. Analysts expect this dividend-paying company to report a third-quarter profit of $4.24 per share, which is 57.3% higher than in the same period of last year. Revenue for the period that ended in September is expected to be $11.0 billion. So far, the full-year forecast is for $17.74 per share on $44.6 billion.

Continue reading Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Vita Nelson: DRIP expert votes for Abbott (ABT)

In her The MoneyPaper, editor Vita Nelson looks to stocks offering dividend reinvestment plans. Here, she highlights Abbott Laboratories (NYSE: ABT) as a featured holding in her model portfolio.

"Abbott is a diversified, multinational, health care firm.The shares have not responded to the recent stock market rallies in part due to the defensive nature of health care stocks.

"Uncertainty regarding health care reform is also a factor in the static share price of recent months. ABT shares are now trading below 11 times 2010 earnings estimates, compared with about 15 for the S&P 500.

Continue reading Vita Nelson: DRIP expert votes for Abbott (ABT)

Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Charles Schwab and Abbott Labs top Q1 estimates

On Wednesday, Charles Schwab Corp. (NASDAQ: SCHW) reported that its lower first-quarter earnings easily topped analysts' estimates, and Abbott Laboratories (NYSE: ABT) said its higher first-quarter profit edged past Wall Street expectations. Shares of Schwab surged while those of Abbott Labs fell Wednesday.

San Francisco-based brokerage and investment manager Charles Schwab said it earned $218 million, or 19 cents per share, for the quarter, as compared to $305 million, or 26 cents per share, in the same period of the previous year. Total revenue fell 15% year over year to $1.11 billion.

Continue reading Charles Schwab and Abbott Labs top Q1 estimates

Abbott (ABT): An 'income machine'

"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.

"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

"The company employs more than 68,000 people and markets its products in more than 130 countries.

"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.

Continue reading Abbott (ABT): An 'income machine'

Turnaround time for drug stocks? 10 top picks

"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.

Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is his overview.

"In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies?

"Demand for their products was growing as the population aged. These companies had huge research
and development programs that seemed to keep cranking out new blockbuster drugs. And most of them had great balance sheets, with many paying handsome dividends.

"Much of this reasoning has been borne out in the intervening years. Many large drug manufacturers have rung up substantial revenue gains over the last decade. So what's happened to the big drug stocks? With few exceptions they have gone sideways or down – in some cases down a lot.

Continue reading Turnaround time for drug stocks? 10 top picks

Earnings highlights: Google, Intel, Coca-Cola, Pfizer, eBay, AMD and others

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Google, Intel, Coca-Cola, Pfizer, eBay, AMD and others

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA-89.2312,801.23
NASDAQ-23.352,903.88
S&P 500-9.311,342.64

Last updated: February 11, 2012: 03:15 PM

Hot Stocks

General Electric

18.875-0.255(-1.33)

Alcoa

10.29-0.35(-3.29)

Apple Inc

493.42+0.25(+0.05)

Google Inc 'A'

605.91-5.55(-0.91)

Bank of America

8.07-0.11(-1.34)

Wal-Mart Stores

61.90-0.06(-0.10)

Exxon Mobil Corp

83.80-1.08(-1.27)

Ford

12.44-0.25(-1.97)

Citigroup

32.925-0.735(-2.18)

IBM

192.42-0.71(-0.37)

Yahoo

16.14+0.14(+0.88)

Starbucks

48.82-0.38(-0.77)

Microsoft

30.495-0.275(-0.89)

Home Depot

45.33+0.06(+0.13)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1328991359520 ms.